scholarly journals The use of botulinum toxin for the treatment of patients with overactive bladder

2019 ◽  
Vol 65 (4) ◽  
Author(s):  
Agnieszka Licow ◽  
Sylwester Ciećwież ◽  
Magdalena Ptak ◽  
Dariusz Kotlęga ◽  
Andrzej Starczewski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Incontinence ◽  
Botulinum Toxin ◽  
Side Effects ◽  
Overactive Bladder ◽  
Therapeutic Option ◽  
Great Promise ◽  
Social Psychological ◽  
Cholinergic Drugs

Overactive bladder affects 12–17% of the population, and mainly women, and its incidence increases with age. Diagnosis of this condition is based mainly on the patients’ complaints. These symptoms significantly affect the quality of life of millions of patients, involving considerable social, psychological, professional, physical and sexual problems. The wide incidence of this condition makes it necessary to find new medical substances in order to effectively eliminate the symptoms. Neurotoxins are a group of medical drugs that hold great promise for the future. Botulinum toxin is currently being used to treat  symptoms related to overactive bladder. It can constitute an appropriate therapeutic option, in  particular with regard to patients for whom the use of standard anti-cholinergic drugs is unsatisfactory or leads to severe side effects. Numerous research studies confirm that botulinum toxin can be  efficiently used in the treatment of overactive bladder. The properties of this neurotoxin allow selective  deactivation of overactive muscles. The use of botulinum toxin can be a method of treatment that significantly improves patient quality of life.Keywords: botulinum toxin; overactive bladder; urinary incontinence; quality of life.

scholarly journals Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

2019 ◽  
Vol 77 (5) ◽  
pp. 346-351 ◽  
Author(s):  
Emanuel de Jesus Soares de Sousa ◽  
Gustavo Celeira de Sousa ◽  
Vitor Ferreira Baia ◽  
Danusa Neves Somensi ◽  
Marília Brasil Xavier
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Botulinum Toxin ◽  
Therapeutic Option ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Chronic Neuropathic Pain ◽  
Specific Protocol

ABSTRACT Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. Objective: To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication. Methods: We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60. Results: Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL. Conclusion: BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients.

Sign in / Sign up

Export Citation Format

Share Document